co-leads CHF 103 million investment in Noema Pharma
Summary
Naarden, The Netherlands 07 March 2023 Forbion, a leading European life sciences venture capital firm, today announces that it has co-led a CHF 103 million (approx. This second Forbion Growth Opportunities Fund invests in mostly European, later-stage biopharma companies, developing novel therapies for areas of high medical need such as CNS conditions. This is the fourth company that we have invested in from our second growth fund, and it reflects the continuing need for late-stage finance in a maturing European life sciences industry.Luigi Costa, Chief Executive Officer of Noema Pharma added, "We are excited to announce the successful completion of this oversubscribed Series B financing round and very pleased to have a world-class group of investors supporting our vision of bringing much-needed treatments to those living with debilitating central nervous system disorders. The Company is also developing gemlapodect (NOE-105), a PDE10a inhibitor which is being evaluated in Phase 2b clinical trials for Tourette Syndrome and Childhood Onset Fluency Disorder (COFD) or Stuttering; and NOE-115, a Phase 2 ready triple reuptake inhibitor for Atypical Depression and Binge Eating Disorder.Read the official company release here.For more information please contact:About Forbion Forbion (www.forbion.com) is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Noema currently has 3 active Phase 2b clinical trials in highly undertreated CNS conditions: seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder.